ScoreComparison
Why is Stoke Therapeutics, Inc. ?
1
Poor Management Efficiency with a low ROE of 2.87%
- The company has been able to generate a Return on Equity (avg) of 2.87% signifying low profitability per unit of shareholders funds
2
The company has declared Positive results for the last 4 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD 61.6 MM
- NET SALES(HY) Higher at USD 172.39 MM
- NET PROFIT(HY) Higher at USD 89.4 MM
3
With ROE of 14.36%, it has a attractive valuation with a 1.74 Price to Book Value
- Over the past year, while the stock has generated a return of 153.14%, its profits have risen by 146.3% ; the PEG ratio of the company is 0.1
4
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
5
Market Beating performance in long term as well as near term
- Along with generating 153.14% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Stoke Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Stoke Therapeutics, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Stoke Therapeutics, Inc.
145.58%
1.37
73.01%
S&P 500
12.66%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
188.80%
EBIT Growth (5y)
23.58%
EBIT to Interest (avg)
-67.33
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.01
Sales to Capital Employed (avg)
0.17
Tax Ratio
2.48%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
2.87%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
12
Industry P/E
Price to Book Value
1.74
EV to EBIT
6.62
EV to EBITDA
5.94
EV to Capital Employed
-50.90
EV to Sales
1.33
PEG Ratio
0.09
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
14.36%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend30What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 61.6 MM
NET SALES(HY)
Higher at USD 172.39 MM
NET PROFIT(HY)
Higher at USD 89.4 MM
ROCE(HY)
Highest at 18.17%
RAW MATERIAL COST(Y)
Fallen by -20.15% (YoY
CASH AND EQV(HY)
Highest at USD 605.18 MM
DEBTORS TURNOVER RATIO(HY)
Highest at 207.47 times
-14What is not working for the Company
INTEREST(9M)
At USD 0 MM has Grown at inf%
NET SALES(Q)
At USD 13.82 MM has Fallen at -71.05%
PRE-TAX PROFIT(Q)
At USD -23.48 MM has Fallen at -282.22%
NET PROFIT(Q)
At USD -23.48 MM has Fallen at -286.85%
DEBT-EQUITY RATIO
(HY)
Highest at -72.92 %
Here's what is working for Stoke Therapeutics, Inc.
Operating Cash Flow
Highest at USD 61.6 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Cash and Eqv
Highest at USD 605.18 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Debtors Turnover Ratio
Highest at 207.47 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -20.15% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Stoke Therapeutics, Inc.
Interest
At USD 0 MM has Grown at inf%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Net Sales
At USD 13.82 MM has Fallen at -71.05%
over average net sales of the previous four periods of USD 47.73 MMMOJO Watch
Near term sales trend is extremely negative
Net Sales (USD MM)
Pre-Tax Profit
At USD -23.48 MM has Fallen at -282.22%
over average net sales of the previous four periods of USD 12.89 MMMOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (USD MM)
Net Profit
At USD -23.48 MM has Fallen at -286.85%
over average net sales of the previous four periods of USD 12.57 MMMOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)
Debt-Equity Ratio
Highest at -72.92 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
